Search

everythinglearnresearchcommunity

for

Search:↓

COVID-19 can cause different types of hair loss, which may last up to 100 days, and treatments are still being explored.

There have been major advances in diagnosing and treating hair loss over the last 30 years, with new drugs and improved hair transplant techniques.

Topical corticosteroids are the best initial treatment for children with Alopecia Areata.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Androgenetic alopecia, a common hair loss condition, can be treated with topical minoxidil, oral finasteride, or oral spironolactone, and new treatments like platelet-rich plasma, low-level laser therapy, and janus-kinase inhibitors are being explored.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Rapamycin treatment helps with mitochondrial disease by reducing PKC levels.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

New treatments for sudden hair loss include oral medications and a special laser, both showing promise in hair regrowth.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

A deficiency in the TTC7A gene causes immune problems, gut issues, and hair loss.

Erlotinib can cause hair loss as a side effect.

The drug combination was safe and showed promise in treating advanced tumors.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

The document concludes that oral finasteride and topical minoxidil are effective for genetic hair loss, while other treatments for different types of hair loss show promise but need more research.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Nilotinib can cause skin issues like red bumps and hair loss.

Blocking certain immune signals can reduce skin damage from radiation therapy.

Disrupted sleep patterns can harm skin and hair cell renewal, but melatonin might help.

Ruxolitinib treatment may cause eyelash growth.

A woman's hair turned white after taking a cancer drug called dasatinib.